PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27168723-5	2015	c-myc activation was inhibited upon treatment with ERK, PI3 kinase, and c-src pathway inhibitors, U0126, LY294002, and PP2.	U 0126	98-103	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5	
29762991-8	2017	Conversely,after U0126 treatment,the expression levels of p-ERK1 /2,c-Myc and vimentin decreased significantly,while E-cadherin expression level increased.	U 0126	17-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	68-73	
27601158-7	2016	Moreover, BaP-induced overexpression of MMP9 and c-myc were attenuated by the ERK inhibitor U0126 and AhR inhibitor resveratrol, respectively.	U 0126	92-97	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	49-54	
34678088-8	2022	PI3K pathway inhibitor LY294002 or MEK pathway inhibitor U0126, or Warburg effect inhibitor DCA was used to carry out western blot and glucose metabolism experiments, and the results showed that PDGFBB/PDGFRbeta mainly activated the PI3K/AKT/mTOR/ c-Myc pathway to promote aerobic glycolysis in osteosarcoma HOS cells.	U 0126	57-62	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	248-253	
32542095-8	2020	U0126 inhibited semen-induced ERK1/2 phosphorylation, c-myc upregulation and cell proliferation.	U 0126	0-5	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59	
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	236-241	
19258428-2	2009	In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model.	U 0126	85-90	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	100-105	
24161621-5	2013	Moreover, expressions of c-Myc, Bad, Bax and ATM in SK-N-BE(2) cell line were significantly increased by U0126+ATO treatment as compared to treatment with ATO alone.	U 0126	105-110	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	25-30	
25304236-8	2014	Although argininosuccinate synthase induction could not be induced in vitro, a drug targeting pathway previously demonstrated to be associated with Ser62 cMyc phosphorylation - U0126 - in combination with CoArgIPEG demonstrated an in-vitro synergistic response (combination indices 0.13+-0.10 and 0.14+-0.10 with or without citrulline, respectively).	U 0126	177-182	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	154-158	
21933022-7	2012	Treatment of U251 and 5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels.	U 0126	45-50	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	89-94	
19258428-4	2009	Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression.	U 0126	104-109	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	163-166	
19258428-4	2009	Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression.	U 0126	104-109	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	171-176	
19258428-6	2009	The RD-M1 cultured xenograft tumor-derived cell line and the ERMS cell line TE671 responded to U0126 by arresting growth, down-regulating c-Myc, and initiating myogenesis.	U 0126	95-100	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	138-143	
18353995-4	2008	Combination with the mitogen-activated protein kinase kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis-(methylthio)butadiene (U0126) reduced MTX- or GE-induced ERK1/2 over-phosphorylation, nearly abolished c-Myc expression, and provoked radical morphological changes in all cells.	U 0126	132-137	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	212-217	
16899113-3	2006	RESULTS: We demonstrate that, in all the tumor cell lines used, the MEK/ERK inhibitor U0126 rapidly induces c-Myc de-phosphorylation, which is followed by a marked reduction in its expression level, by inhibition of proliferation and by reversion of anchorage-independent growth.	U 0126	86-91	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	108-113	
16899113-6	2006	Moreover, ectopic MadMyc chimera, a c-Myc function antagonist, causes dramatic growth arrest, CDK and cyclin modulation as well as inhibition of anchorage-independent growth in RD cells, as occurs in U0126-treated cells.	U 0126	200-205	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	36-41	
18086564-5	2008	The proliferation of EoL-1 cells and expression of c-Myc were also inhibited by the MEK inhibitor U0126 and JNK inhibitor SP600125.	U 0126	98-103	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56	
16596619-4	2006	Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression.	U 0126	151-157	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	29-34	
16596619-4	2006	Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression.	U 0126	151-157	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	216-221